Forest launches COPD product Tudorza in USA

12 December 2012

Forest Laboratories has started to roll out its new chronic obstructive pulmonary disease (COPD)
product Tudorza Pressair in US pharmacies, following launches in Germany, the UK and Denmark by
the drug's originator Almirall.

Tudorza (aclidinium bromide) was approved by the US Food and Drug Administration (FDA) in July
for the long-term maintenance treatment of bronchospasm associated with COPD, including chronic
bronchitis and emphysema (The Pharma Letter July 24).

The product contains a long-acting muscarinic antagonist (LAMA) and is entering a market
dominated by Boehringer Ingelheim and Pfizer's LAMA Spiriva (tiotropium) as well as
GlaxoSmithKline's LABA/corticosteroid combination Advair/Seretide/Adoair (salmeterol plus
fluticasone).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK